The latest data point for Pfizer's (PFE) Operation Income in Q1'26 shows a positive figure of $4.03B USD, marking a sequential improvement from the $1.64B loss in Q4'25 and reflecting a modest year-over-year growth of 44.8%. This rebound contributes to a recent uptick in quarterly performance, following a volatile period of alternating profits and losses. Over the timeframe from Q2'23 to Q1'26, Operation Income exhibits high volatility with an overall trend of stabilization toward positive territory in the latter half, starting from a $2.27B profit in Q2'23 that deteriorated into deepening losses peaking at -$4.13B in Q4'23, before recovering with notable gains like $4.72B in Q3'24 and consistent positives exceeding $2.78B from Q1'25 onward except for Q4'25. Year-over-year changes underscore this instability, with sharp declines exceeding -80% in early quarters giving way to strong recoveries such as +2,407% in Q3'24 and +3,027% in Q2'25, though Q4'25 saw a drastic -16,340% drop; the bar chart highlights these swings, while the overlaid line chart for YoY percentages emphasizes the transition from negative to predominantly positive growth momentum by Q1'26.